Mirmosayyeb O, Shaygannejad V, Ebrahimi N, Ghoshouni H, Ghajarzadeh M
Department of Neurology, School of Medicine, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
Neurologia (Engl Ed). 2025 Jan-Feb;40(1):41-47. doi: 10.1016/j.nrleng.2022.07.004. Epub 2022 Aug 30.
To estimate the pooled prevalence of cancer in patients with multiple sclerosis (MS) cases who were under treatment with rituximab.
We searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021. The search strategy included the MeSH and text words as (("CD20 Antibody" AND Rituximab) OR "Rituximab CD20 Antibody" OR Mabthera OR "IDEC-C2B8 Antibody" OR "IDEC C2B8 Antibody" OR IDEC-C2B8 OR "IDEC C2B8" OR GP2013 OR Rituxan OR rituximab) AND ((Sclerosis AND multiple) OR (sclerosis AND disseminated) OR "disseminated sclerosis" OR "multiple sclerosis" OR "acute fulminating").
The literature search revealed 3577 articles, after deleting duplicates 2066 remained. For the meta-analysis, 22 studies were included. Totally, 15599 patients were enrolled while 133 cancers were detected. The pooled prevalence of cancer in MS patients under treatment with rituximab is 1in 100,000 (I2 = 99.9%, p < 0.001).
The results of this systematic review and meta-analysis show that the pooled prevalence of cancer in MS patients who received rituximab is 1 in 100,000 cases.
评估接受利妥昔单抗治疗的多发性硬化症（MS）患者中癌症的合并患病率。
我们检索了截至2021年4月的PubMed、Scopus、EMBASE、Web of Science和谷歌学术，以及灰色文献。检索策略包括医学主题词（MeSH）和文本词，如（（“CD20抗体”和利妥昔单抗）或“利妥昔单抗CD20抗体”或美罗华或“IDEC-C2B8抗体”或“IDEC C2B8抗体”或IDEC-C2B8或“IDEC C2B8”或GP2013或美罗华或利妥昔单抗）以及（（硬化症和多发性）或（硬化症和播散性）或“播散性硬化症”或“多发性硬化症”或“急性暴发性”）。
文献检索共找到3577篇文章，删除重复项后还剩2066篇。纳入荟萃分析的有22项研究。总共纳入了15599例患者，检测到133例癌症。接受利妥昔单抗治疗的MS患者中癌症的合并患病率为十万分之一（I2 = 99.9%，p < 0.001）。
该系统评价和荟萃分析的结果表明，接受利妥昔单抗治疗 的MS患者中癌症的合并患病率为十万分之一。
